On Wednesday, March 20, the Federal Circuit ruled that “discovery is not allowed in inter partes patent reexaminations.” The finding denies a bid by Cordis Corp. to subpoena Abbott Laboratories for discovery in an inter partes proceeding before the U.S. Patent and Trademark Office (USPTO). The decision noted that the Patent Act allows district courts to issue subpoenas in “any contested case” at the USPTO. The Federal Circuit found that reexaminations are not “contested.” Finnegan represented Abbott in this matter.
Press Release
October 6, 2026
Commentary
Federal Circuit Revives Whistleblower Complaint Over VA's AI Claims-Processing Tool
September 25, 2026
Award/Ranking
Finnegan Named an IP Litigation Powerhouse in BTI Litigation Outlook 2027
September 24, 2026
Press Release
Finnegan Secures Precedential Pro Bono Federal Circuit Victory for AI Whistleblower
September 23, 2026
Award/Ranking
Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026
September 23, 2026
Commentary
FORUM IP Talks: Dr. Jochen Herr on UPC, FRAND, and Cross-Border Enforcement Topics
September 20, 2026
Commentary
Pepsi's U.S. Trademark Dispute Could Reshape Brand Choices, Lawsuit Strategy, Lawyers Say
September 17, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.